Sangui Biotech International, Inc. Announces Sales Results for the Fourth Quarter Ended June 30, 2014; Provides Sales Guidance for the Full Financial Year 2014
July 29, 2014 at 11:50 am EDT
Share
Sangui Biotech International Inc. announced sales results for the fourth quarter ended June 30, 2014. For the period, the company yielded revenues from royalties and product sales of USD 42,000, in the fourth quarter of its financial year 2013 the company reported revenues of USD 24,056.
The company provided sales guidance for the full financial year 2014. Based on this preliminary state of accounting Sangui will presumably present revenues of more than USD 130,000 for its 2014 financial year.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
Sangui Biotech International, Inc. Announces Sales Results for the Fourth Quarter Ended June 30, 2014; Provides Sales Guidance for the Full Financial Year 2014